- Home
- IBIO vs SYBX Comparison
IBIO vs SYBX Comparison
Compare IBIO & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- SYBX
- Stock Information
- Founded
- IBIO 2008
- SYBX N/A
- Country
- IBIO United States
- SYBX United States
- Employees
- IBIO N/A
- SYBX N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- IBIO Health Care
- SYBX Health Care
- Exchange
- IBIO Nasdaq
- SYBX Nasdaq
- Market Cap
- IBIO 16.4M
- SYBX 16.4M
- IPO Year
- IBIO N/A
- SYBX N/A
- Fundamental
- Price
- IBIO $0.87
- SYBX N/A
- Analyst Decision
- IBIO Strong Buy
- SYBX
- Analyst Count
- IBIO 2
- SYBX 0
- Target Price
- IBIO $5.50
- SYBX N/A
- AVG Volume (30 Days)
- IBIO 376.3K
- SYBX 17.3K
- Earning Date
- IBIO 11-11-2025
- SYBX 11-11-2025
- Dividend Yield
- IBIO N/A
- SYBX N/A
- EPS Growth
- IBIO N/A
- SYBX N/A
- EPS
- IBIO N/A
- SYBX N/A
- Revenue
- IBIO $400,000.00
- SYBX N/A
- Revenue This Year
- IBIO N/A
- SYBX N/A
- Revenue Next Year
- IBIO N/A
- SYBX N/A
- P/E Ratio
- IBIO N/A
- SYBX N/A
- Revenue Growth
- IBIO 77.78
- SYBX N/A
- 52 Week Low
- IBIO $0.56
- SYBX $0.90
- 52 Week High
- IBIO $6.89
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- IBIO 60.39
- SYBX 57.52
- Support Level
- IBIO $0.78
- SYBX $1.61
- Resistance Level
- IBIO $0.86
- SYBX $1.74
- Average True Range (ATR)
- IBIO 0.04
- SYBX 0.07
- MACD
- IBIO 0.00
- SYBX -0.01
- Stochastic Oscillator
- IBIO 95.55
- SYBX 50.00
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.